6010-3724505 admin@juzlab.net
0 Items
A company that calls itself the ‘Flatiron Health of rare diseases’ and is backed by Mark Zuckerberg, Bill Gates, and Jeff Bezos just raised $3 million

A company that calls itself the ‘Flatiron Health of rare diseases’ and is backed by Mark Zuckerberg, Bill Gates, and Jeff Bezos just raised $3 million

RDMD co-founders Nancy Yu and Onno Faber.

caption
RDMD co-founders Nancy Yu and Onno Faber.
source
RDMD
  • RDMD is a platform for data sharing between patients with rare diseases, doctors, and researchers.
  • The company announced on Monday it har raised $3 million in seed funding led by Lux Capital and Village Global, whose network of backers include Bill Gates, Mark Zuckerberg, Jeff Bezos, and Reid Hoffman.

When Onno Faber was diagnosed in 2014 with a rare disease called neurofibromatosis type 2 that creates tumors in the central nervous system, he blindly combed through the Internet for treatment options before a friend who was doing genetic research suggested a potential clinical trial.

He soon realized there had to be a better way.

Faber then teamed up with former 23andMe executive Nancy Yu to found RDMD, a platform that works with patients, top experts and foundations to collect patient data on their history and symptoms. These records help patients share their data with doctors, get second opinions, and coordinate ongoing care. Patients can also give consent to share biomarkers for drug development and possible clinical trial developments.

On Monday, RDMD announced $3 million in seed funding led by Lux Capital and Village Global, whose network of backers include Bill Gates, Mark Zuckerberg, and Jeff Bezos.

Faber likens RDMD to the “Flatiron Health of rare diseases” since it provides a searchable database for patients, researchers and doctors that makes patient data usable for research and drug development purposes.

The problem in the rare disease sector is that there aren’t that many doctors, patients or researchers so it takes a long time to collect enough clinical data to do research. The goal of RDMD is to create a platform that can shorten the timeline for research and development of treatments for rare disease.

“We wanted to bridge the gap between the patient community and the science community,” said Faber.

To date, 150 patients have signed up on RDMD for neurofibromatosis. Although the platform hosts just one rare disease right now, Yu said that the long-term goal of the company is to expand to different types of rare diseases. They also hope to partner with biotech and pharmaceutical companies in the future.

See also:

The pill that can diagnose disease

The pill that can diagnose disease

In the 1966 science fiction classic movie Fantastic Voyage, a submarine crew is miniaturised so it can squeeze inside a human body and travel to a hot spot where medical assistance is needed.

A team from the Massachusetts Institute of Technology (MIT), United States, has adapted this idea for real life, replacing the shrunken squad with specially-engineered Escherichia coli bacteria and pairing them with a suite of electronics that fit neatly inside an ingestible pill.

They call their creation an IMBED – short for ingestible micro-bioelectronic device – and used it to detect excess blood in the stomachs of pigs.

After finding blood, the capsule sent a wireless signal from within the pig’s body that was read by a smartphone and a laptop computer.

Other IMBEDs outfitted with different bacteria were able to detect one molecule that signals inflammation inside the gut and another that’s a biomarker for gastrointestinal (GI) infections.

Although IMBEDs are still years away from being used in patients, gastroenterologists say they are already eager to get their hands on them.

“This has the potential to unlock a wealth of information about the body’s structure and function, its relationship with the environment, and the impact of disease and therapeutic interventions,” Dr Peter Gibson and Dr Rebecca Burgell of Australia’s Monash University wrote in a commentary that accompanies the study.

IMBEDs combine advances in synthetic biology with improvements in electrical engineering.

Inside the capsule are four wells that contain genetically-engineered E. coli bacteria. These biosensors have been modified to recognise a particular molecule of interest, such as the blood component heme.

A semi-permeable membrane traps the biosensors inside the capsules, but allows molecules from the environment to enter and be detected.

Once the target is identified, the bacteria metabolise it in a process that generates light through bioluminescence.

Beneath each well is a tiny electronic photodetector that can register light from the bacteria. A luminometer chip converts it into a digital signal, and a wireless transmitter sends that signal outside the body.

The MIT researchers, led by microbiology graduate student Mark Mimee and electrical engineering researcher Phillip Nadeau, put the IMBEDs through their paces in the stomachs of six pigs.

After the pigs were sedated, the scientists used an endoscope to deliver about one cup of solution into the pigs’ stomachs. Three of the pigs also got a tiny amount of pig blood.

Next, the team placed two IMBEDs in each pig’s stomach and used the endoscope to confirm that they were fully submerged.

It took 52 minutes for the biosensors to recognise the blood, generate light and transmit the signal to the scientists.

The signals grew stronger until the IMBEDs were removed two hours after the experiment began.

The IMBEDs correctly identified which three pigs had blood in their stomachs and which three did not, according to the study.

Other experiments outside of animals showed that the IMBEDs could recognise – and respond to – molecules that signal problems in the human gut.

The IMBEDs used in the study were 30 millimeters (a little more than one inch) long and 10 mm across.

Timothy Lu, a senior author of the study and Mimee’s advisor, acknowledged that the devices were “on the larger side”, but added: “I think for someone who’s motivated, they could definitely swallow it.”

Nadeau said he was optimistic that future IMBEDs could be at least one-third smaller than they are today by combining the luminescence detector, the microprocessor and the wireless transmitter onto a single chip. That would make it more palatable for patients.

“The idea would be you would swallow it and it would pass through the GI tract and eventually you would excrete it,” he said.

Lu said IMBEDs might eliminate the need for colonoscopies. Not only are colonoscopies uncomfortable, but the bowel prep required in advance of the exam alters the physiology inside the intestines, potentially masking signs of disease.

Dr Gibson and Dr Burgell described a future in which smaller IMBEDs could be placed into blood vessels to assess conditions in the circulatory system.

Other versions could be implanted in solid organs – just like the five heroes of Fantastic Voyage who ventured inside a brain to remove a life-threatening blood clot.

“It is exciting to watch where this technology ultimately takes us,” they wrote. – Los Angeles Times/Tribune News Service

Pin It on Pinterest